The best products are often developed when the product manager is also a customer, or in the case of biotech, when the CEO is also a patient. Hear from Nick Sireau of Serenatis Bio, who developed a product that’s on the market for an ultra-rare disease, and is now preparing for a series A raise for an OCD asset after a successful seed raise. Nick’s story, including how Life Science Nation’s training, data, and events helped him, is an inspiring tale of keeping the patient first while navigating the labyrinth of the investment landscape. When Nick one day received a newsletter from Dennis Ford, CEO of LSN, saying that you need 600 – 800 investor leads to do a successful raise, he re-evaluated his strategy and realized it was a numbers game, and he had to play it fast. He searched LSN’s investor database of thousands of investors to find the best fits in the least amount of time, and participated in training from Greg Mannix, VP of International Business Development of LSN, on how to pitch and optimize partnering strategies. Now he’s on the hopeful path of bringing a treatment to a condition that is absolutely devoid of good treatment options, that can dramatically reduce quality of life and even lead to suicide. If you are an entrepreneur fundraising, this video will give you sage advice that you can use right away to accelerate your raise.
Next Phase Newsletter 
Leave a comment